Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: Further exploring the role of P53 and WT1 gene

Pathology

Volumn 41, Issue 2, 2009, Pages 127-132

  Huang, Wan Ting ^a   Huang, Chao Cheng ^a   Weng, Shao Wen ^a   Eng, Hock Liew ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

MDR; Multidrug resistance protein; Nasal NK T cell lymphoma; NKTL; P53; WT1

Indexed keywords

LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; WT1 PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; MULTIDRUG RESISTANCE; MUTATION; NK T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; T LYMPHOCYTE RECEPTOR GENE;

EID: 61649109806     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802441683     Document Type: Article

References (32)

1. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-7.
2. Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-9.
3. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666-70.
4. Kang YK, Zhan Z, Regis J, et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995; 86: 1515-24.
5. Zhan Z, Sandor VA, Gamelin E, et al. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 1997; 89: 3795-800.
6. Cheng AL, Su IJ, Chen YC, et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109-15.
7. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467-73.
8. Cho EY, Gong G, SK, et al. Fine needle aspiration cytology of CD56-positive natural killer/T-cell lymphoma of soft tissue. Cancer 2002; 96: 344-50.
9. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
10. Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996; 65: 230-7.
11. Filipits M, Drach J, Pohl G, et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999; 5: 2426-30.
12. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-9.
13. Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-13.
14. Borg AG, Burgess R, Green LM, et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083-91.
15. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-8.
16. Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 2001; 98: 1160-5.
17. Chen W, Cooper N R. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. J Virol 1996; 70: 4849-53.
18. Kim GE YW, Lee SW, Rha SY, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004; 45: 1857-64.
19. Oka M, Kounoura K, Narasaki F, et al. P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997; 88: 738-42.
20. Drakos E RG, Tsioli P, Lai R, et al. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 2005; 13: 132-7.
21. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002; 19: 87-104.
22. Ohsawa MIY, Fukushima H, Shirai N, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005; 68: 422-31.
23. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-62.
24. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998; 58: 5762-9.
25. Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000; 80: 493-9.
26. Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol 1999; 30: 849-55.
27. Takahara M, Kishibe K, Bandoh N, et al. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 2004; 35: 86-95.
28. Szekely L, Pokrovskaja K, Jiang WQ, et al. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns. Oncogene 1995; 10: 1869-74.
29. Gulley ML, Burton MP, Allred DC, et al. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum Pathol 1998; 29: 252-9.
30. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-12.
31. Menke AL, Clarke AR, Leitch A, et al. Genetic interactions between the Wilms' tumor 1 gene and the p53 gene. Cancer Res 2002; 62: 6615-20.
32. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-9.